with precision+
Developing next-generation biologics designed to selectively eliminate or reprogram pathogenic immune cells in autoimmune diseases.
Anaveon is a late stage preclinical biotech company headquartered in Basel, Switzerland + focused on developing engineered antibodies that target central regulatory nodes of the immune system.
Immune-mediated diseases arise from dysregulation of key pathways controlling immune activation and tolerance. Rather than targeting individual downstream mediators, our precision biologics act on upstream immune pathways to selectively eliminate or reprogram pathogenic immune cells and restore durable immune balance.
Transforming Autoimmunity Through Deep Depletion of Pathogenic T cells
ANV200 is a next-generation, precision-engineered antibody,
designed for deep depletion of PD-1-expressing immune cells that drive pathogenic immune responses and persistent inflammation in autoimmune diseases.
Its ability to target the full spectrum of PD-1-expressing pathogenic T cells gives ANV200 the potential to influence multiple downstream disease mechanisms. By acting on a key control point in the immune system, ANV200 is intended to reset harmful immune responses and restore tissue homeostasis. ANV200 is currently in preclinical development, with clinical testing planned in the near future.
Executive Team
Thaminda Ramanayake
Chief Executive Officer
Thaminda brings more than two decades of global biotechnology and pharmaceutical leadership experience, with a focus on building companies and advancing innovative therapeutics. Prior to joining Anaveon, he served as Chief Business Officer at CureVac, where he played a central role in the company’s transformation and its acquisition by BioNTech. He previously held senior leadership roles at Sanofi, Affini-T Therapeutics, BioMarin, and Amgen, leading strategic transactions and partnerships across multiple therapeutic areas.
Throughout his career, Thaminda has operated at the intersection of science and strategy—helping translate breakthrough biology into differentiated medicines and scalable platforms. He is also a Venture Partner at Entrée Bioventures, a premier biotechnology investment fund incubated within Entrée Capital. Thaminda holds a B.A. in Cellular Biology from Berea College and earned his M.S. in Immunology and MBA in Finance from the University of Rochester.
Throughout his career, Thaminda has operated at the intersection of science and strategy—helping translate breakthrough biology into differentiated medicines and scalable platforms. He is also a Venture Partner at Entrée Bioventures, a premier biotechnology investment fund incubated within Entrée Capital. Thaminda holds a B.A. in Cellular Biology from Berea College and earned his M.S. in Immunology and MBA in Finance from the University of Rochester.
Christoph Huber
Chief Scientific Officer
Christoph brings more than 15 years of experience in immunology, inflammation, and immuno-oncology, spanning discovery research, translational science, and early clinical development. Before joining Anaveon, he held leadership roles at Roche, Pfizer, and PDI Therapeutics. Across his career, he has led multidisciplinary teams advancing programs from target identification and validation through IND/CTA-enabling development into Phase 1, supporting the progression of innovative therapeutic modalities and programs. Christoph completed his postdoctoral training in immunology at The Scripps Research Institute and earned his Ph.D. in Molecular Biology from the University of Zurich.
Latest News
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer
Basel, Switzerland, March 23, 2026 – Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda Ramanayake as its new Chief Executive Officer.
Mr. Ramanayake brings over 20 years of global biopharmaceutical leadership experience, with a strong track record in business development, strategic transactions, and advancing innovative therapeutics. Most recently, as Chief Business Officer at CureVac, he played a key role in the company’s transformation and its acquisition by BioNTech in 2025. He previously held senior business development and strategy roles at Sanofi, Affini-T Therapeutics, BioMarin, and Amgen, leading partnerships, licensing, and M&A initiatives. He holds an M.S. in Immunology and an MBA from the University of Rochester, New York.
Dieter Weinand, Chair of the Anaveon Board of Directors, said, “Thaminda is a proven leader with deep strategic and transaction expertise. His ability to build and position companies for value creation makes him ideally suited to lead Anaveon as we advance our immunology pipeline toward the clinic. As we sharpen our focus on immunology, we are confident that Thaminda’s leadership will accelerate our ambition to become a premier immunology company based in Switzerland.”
“It is an honor and an exciting challenge to serve as the next Chief Executive Officer of Anaveon,” said Mr. Ramanayake. “Anaveon is developing new ways to precisely control T cells to address significant unmet needs in autoimmune and inflammatory diseases. With promising data across our growing pipeline, including our lead asset ANV200, as a best-in-class candidate for robust depletion of pathogenic T cells, we have tremendous opportunities to make a meaningful difference for patients. I look forward to partnering with the team to drive this next phase of growth and innovation.”
Christoph Huber, Chief Science Officer, added, “Building on our strong scientific expertise, we are well positioned to translate these advances into differentiated therapies and drive the company’s next phase of growth. We look forward to working with Thaminda to deliver impactful therapies for patients.”
Andreas Katopodis, who has led Anaveon since its launch, commented, “I am proud of the foundation we have built and confident that Thaminda’s leadership will guide Anaveon through its next stage of growth and development.”
Dieter Weinand continued, “On behalf of the Board, I would like to thank and recognize Andreas for his contribution in leading Anaveon from concept to a promising portfolio of programs, each with the potential to fulfill Anaveon’s mission of delivering meaningful new medicines for patients.”
ENDS
Media contact:
Benz Advisory
Beatrix Benz
Email: beatrix.benz@anaveon.com
Tel: +41 79 256 77 73
About Anaveon:
Anaveon AG is a late-stage preclinical biotechnology company headquartered in Basel, Switzerland. The company is dedicated to transforming lives by precisely modulating the immune system to address high unmet needs in autoimmune diseases and inflammatory disorders. Our therapeutics target central regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells and restore durable immune balance. Anaveon is backed by Syncona, Forbion, Blue Owl, Novartis Venture Fund, Pfizer Ventures and Pontifax.
Our Investors
Located in Basel, Switzerland
© 2026 Anaveon AG | Privacy Policy |
Credits
Corporate Positioning & Design,Concept, Webdesign & Code:
Schlatter corporate GmbH
Mittleres Hofgässlein 1
CH-9000 St.Gallen
Privacy Policy
Data protection and security are important to Anaveon AG (“Anaveon”, “we”). This Privacy Policy describes how we collect and process your personal data when you visit our website www.anaveon.com and its subdomains (“Website”).Personal data we collect and process in order to make this Site available You can visit our Website and obtain information about us and our services without telling us who you are. As with any connection with a webserver, however, the server of our webhosting provider logs and temporarily stores certain technical data. Such data includes the IP address and operating system of your device, the data and time of access, or the type of browser you use to access this Site. This is required for technical reasons. To the extent we, thereby, process personal data, we do so based on our interest in making this Site available and providing you with the best possible user experience.
Data we collect and process in order to respond to your inquiries If you choose to get in touch with us via our contact page, you will be required to complete an electronic submission form providing your name, contact email address, contact phone number and any other information you deem relevant. By clicking the submit button, the information provided will be sent to us and we will process such information in order to send you the information you have requested.
Why and how we use cookies We use cookies on this Site to provide you with the best possible user experience and to help us improve our services. Cookies are text files that are downloaded to your computer or mobile device when you visit a website or use an application. Our Website uses Google Analytics cookies. Information specific to Google Analytics can be found in the next section, including tools to prevent Google Analytics using cookies and tracking your site usage.
Google Analytics This Website uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses “cookies”, which are text files placed on your computer, to help the Website analyse how users use the site. The information generated by the cookie about your use of the Website (including your IP address) will be transmitted to and stored by Google on servers in the United States. Google will use this information for the purpose of evaluating your use of the Website, compiling reports on website activity for website operators and providing other services relating to website activity and internet usage. Google may also transfer this information to third parties where required to do so by law, or where such third parties process the information on Google’s behalf. Google will not associate your IP address with any other data held by Google. You may refuse the use of cookies by selecting the appropriate settings on your browser. However, please note that if you do this you may not be able to use the full functionality of this Website. By using this Website, you consent to the processing of data about you by Google in the manner and for the purposes set out above. To opt out of being tracked by Google Analytics across all websites visit tools.google.com/dlpage/gaoptout. Compatible with Chrome, Internet Explorer 8–11, Safari, Firefox and Opera.
How we process and protect your personal data; how long we store it We collect and process your personal data responsibly, and only for the purposes for which it was intended, as set forth in this Privacy Policy or in accordance with applicable laws. The personal data we collect about you via the contact form will not be revealed or transferred to any third parties. We apply adequate technical and organizational security measures, commensurate with the level of known risk, in order to protect the confidentiality and integrity of the personal data we collect on this Website. We store your personal data only for as long as this is necessary for us to fulfil the purposes for which the data was collected, or, where applicable, for as long as Anaveon is legally required to retain the data.
Third party website links We may direct you to third party websites from content within our site. Linked sites will have their own privacy notices, policies and use of cookies, which we suggest you review in order to understand their procedures for collecting, using and disclosing personal information.
Applications Applications of any kind (job offers, internships, diploma theses, unsolicited job applications), which we receive by e-mail, including all data of the applicant and attachments, are only processed by the human resources department and the respective specialist department in order to assess if your profile fits one of our advertised job offers and/or if we will offer you a job that fits your profile. We also process your data for the initiation of an employment relationship with you, if applicable. Your data will be deleted no later than three months after the application procedure has been completed. Moreover, your data will only be further processed if it is necessary due to statutory retention requirements or if it is necessary for maintaining and/or asserting any legal rights. Data is only disclosed to the extent that is required for the purposes mentioned above; as far as possible, data is only disclosed within our company.
The rights you have regarding your personal data You have certain individual rights regarding the personal data that we collect and process about you through the Website. You have the right to access or receive certain information regarding the personal data we process. You also have a right to have your personal data rectified, to object to the processing of your personal data, or to ask us to restrict processing or delete your personal data. Please note, however, that your rights are subject to exceptions or derogations. Where legally permitted to do so, we may refuse your request to exercise these rights. Specifically, we may need to further process and retain your personal data to perform a contract with you or your company or organization, to comply with legal obligations or to protect our own legitimate interests. In any event, you have a right to lodge a complaint with a competent supervisory authority. If you have submitted information to us, you may get in contact via email to dataprotection@anaveon.com at any time to ask for a copy of the information we hold about you and to have any mistakes corrected or apply any updates.
Contacting us If you have any questions or would like to make use of your above-mentioned rights (concerning access, rectification or deletion of personal data), please send an email to dataprotection@anaveon.com. or write to us at: Anaveon AG, Hochbergerstrasse 60C, CH-4057 Basel, Switzerland
Changes to this Privacy Policy We reserve the right to amend this Privacy Policy at any time and will post any revisions on this page.
Privacy Policy effective date: 17 May 2020, updated on 03 March 2021.